- Home
- CISO vs IGC Comparison
CISO vs IGC Comparison
Compare CISO & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- IGC
- Stock Information
- Founded
- CISO 2015
- IGC 2005
- Country
- CISO United States
- IGC United States
- Employees
- CISO N/A
- IGC N/A
- Industry
- CISO Computer Software: Prepackaged Software
- IGC Biotechnology: Pharmaceutical Preparations
- Sector
- CISO Technology
- IGC Health Care
- Exchange
- CISO Nasdaq
- IGC Nasdaq
- Market Cap
- CISO 31.4M
- IGC 39.8M
- IPO Year
- CISO N/A
- IGC N/A
- Fundamental
- Price
- CISO $1.26
- IGC $0.41
- Analyst Decision
- CISO
- IGC Strong Buy
- Analyst Count
- CISO 0
- IGC 2
- Target Price
- CISO N/A
- IGC $4.00
- AVG Volume (30 Days)
- CISO 671.4K
- IGC 1.4M
- Earning Date
- CISO 11-17-2025
- IGC 11-11-2025
- Dividend Yield
- CISO N/A
- IGC N/A
- EPS Growth
- CISO N/A
- IGC N/A
- EPS
- CISO N/A
- IGC N/A
- Revenue
- CISO $28,792,765.00
- IGC $1,327,000.00
- Revenue This Year
- CISO N/A
- IGC $15.26
- Revenue Next Year
- CISO N/A
- IGC $3.41
- P/E Ratio
- CISO N/A
- IGC N/A
- Revenue Growth
- CISO N/A
- IGC 24.95
- 52 Week Low
- CISO $0.30
- IGC $0.25
- 52 Week High
- CISO $3.84
- IGC $0.50
- Technical
- Relative Strength Index (RSI)
- CISO 64.62
- IGC 53.86
- Support Level
- CISO $1.21
- IGC $0.38
- Resistance Level
- CISO $1.47
- IGC $0.47
- Average True Range (ATR)
- CISO 0.11
- IGC 0.03
- MACD
- CISO 0.03
- IGC -0.00
- Stochastic Oscillator
- CISO 64.52
- IGC 41.00
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.